Salivary Inflammatory Biomarkers: Predictors & Comparative Effects of Sonicare/Elite-Flexcare in Stages of Perio Disease

Inflammation Clinical Trial

Official title:

Studies of Salivary Inflammatory Biomarkers During Biofilm Overgrowth: Confirmation of Predictors and Comparative Effects of Sonicare/Elite-Flexcare in Various Stages of Periodontal Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02187185
• Other study ID #: 09-0627
• Status: Completed
• Phase: N/A
• Start date: April 2009
• Est. completion date: March 2012

Study information

• Verified date: January 2017
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study has 2 aims. One aim is to see if saliva testing can show if a person has healthy gum tissue, gingivitis, or one of three degrees of periodontitis - mild, moderate, or severe. The second aim is to examine the effect of the Sonicare Elite/Flexcare toothbrush on periodontitis.

Description:

Randomized controlled trial to determine clinical and inflammatory benefits of Sonicare Flexcare tooth brushing following experimental induction of biofilm overgrowth in various periodontal conditions.

This research study has both a Diagnostic Aim and a Treatment Aim. Aim #1 is to examine the utility of candidate inflammatory biomarkers within saliva to discriminate between health, gingivitis, mild, moderate and severe periodontis; and to discriminate between active versus inactive states of periodontal disease to see if these basal levels can predict the clinical response to biofilm overgrowth among various periodontal conditions; Aim #2 is to extend the claim of the anti-inflammatory and anti-infective efficacy of the Sonicare/Elite-Flexcare as compared to manual brushing to include 4 levels of periodontal disease [BGI-G, P1, P2 and P3].

The devices used in this study are subject only to Class I (general controls) and considered exempt from the premarket notification procedures and not subject to section 510(k), 515, or 520(m,) of the FDC Act in order to be legally marketed. Thus, the study does not meet the definition of an Applicable Clinical Trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 175
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. adult males or females between the ages of 18 and 75 years (inclusive).

2. able and willing to follow study procedures and instructions.

3. read, understood and signed an informed consent form.

4. present with at least 8 teeth in the functional dentition with a minimum of 3 adjacent teeth with interproximal papilla in each posterior sextant that will have the stent.

5. be in good general health.

6. present with one of the following five categories to be considered for enrollment

• BGI health (all PD<3mm, BOP<10%)

• BGI-gingivitis (all PD=3mm, BOP=10%)

• BGI-P1 (1+ site with PD>3mm, BOP=10%)

• BGI-P2 (1+ site with PD>3mm, BOP>10% but BOP=50%)

• BGI-P3 (1+ site with PD>3mm, BOP>50%)

Exclusion Criteria:

1. chronic disease with oral manifestations or active infectious diseases such as hepatitis, HIV or tuberculosis.

2. gross oral pathology.

3. treatment with antibiotics for any medical or dental condition within 1 month prior to the screening examination.

4. chronic treatment (i.e., two weeks or more) with any medication known to affect periodontal status (e.g., phenytoin, calcium antagonists, cyclosporin, anticoagulants, non-steroidal anti-inflammatory drugs, high dose aspirin such as >100mg per day) within one month of the screening examination.

5. ongoing medications initiated less than three months prior to enrollment (i.e., medications for chronic medical conditions must be initiated at least three months prior to enrollment).

6. clinically significant organ disease including impaired renal function, and/or any bleeding disorder.

7. severe unrestored caries, or any condition that is likely to require antibiotic treatment during the study, including the need for prophylactic antibiotic.

8. use any tobacco products or who have used tobacco products within the previous six months of the screening examination.

9. pregnant, or expect to become pregnant within the next three months and individuals nursing.

10. dental appliances that will interfere with stent construction.

Related Conditions & MeSH terms

• Inflammation
• Periodontitis

Intervention

Other:
• Sonicare/Elite-Flexcare Toothbrush
Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
• Manual Toothbrush
traditional (non-mechanical) toothbrush with nylon bristles and plastic handle

Locations

Country	Name	City	State
United States	The University of North Carolina at Chapel Hill School of Dentistry	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill	Philips Oral Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in (inflammatory biomarkers?) among a range of periodontal disease groups after using Sonicare Elite/Flexcare versus manual toothbrush for four weeks.		Four weeks
Secondary	Identification of salivary biomarkers that can distinguish between and among the 5 disease categories (health, gingivitis, and 3 levels of periodontal disease).		4 weeks